Minerva Surgical, Inc.
Minerva Surgical, Inc. (UTRS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
utrs · stock forecast · 4 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$100
Consensus
$100
+99999903.0% upside
Low
$100
Median: $100 · Last Close: $0.00
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.00 | ↑ 0.00% |
1-day model range: $0–$0. Peak: $0 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · UTRS · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-05-03 | Piper Sandler | Maintains | Overweight→Overweight |
| 2023-05-02 | Piper Sandler | Maintains | Overweight→Overweight |
| 2022-08-10 | Piper Sandler | Maintains | Overweight→Overweight |
| 2022-08-10 | JP Morgan | Downgrade ↓ | Overweight→Underweight |
| 2022-08-09 | Piper Sandler | Maintains | Overweight→Overweight |
| 2022-08-09 | JP Morgan | Downgrade ↓ | Overweight→Underweight |
| 2022-05-12 | SVB Leerink | Maintains | Outperform→Outperform |
| 2022-05-12 | Piper Sandler | Maintains | Overweight→Overweight |
| 2022-05-11 | Piper Sandler | Maintains | Overweight→Overweight |
| 2022-05-11 | SVB Leerink | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Minerva Surgical, Inc. (UTRS) stock. Of the recent 17 rating actions, 0 were upgrades and 2 were downgrades. 4 analysts currently cover UTRS.
Analyst Recommendation Trends
UTRS analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$52M
↓ 0.2% YoY
Revenue Next Year
$51M
↓ 1.4% YoY
EPS This Year
$-67.45
EPS Next Year
$-25.20
↓ 62.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast UTRS EPS of $-67.45 for the current fiscal year, based on estimates from 1 analysts. The UTRS revenue forecast is $52M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The UTRS stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus UTRS price target is $100.00 (+99999903.0% upside), with an analyst consensus of Buy.
The UTRS short-term stock prediction for tomorrow is $0.00 (+0.00%).
Minerva Surgical, Inc. trades on OTC under the ticker UTRS. The UTRS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 75% of covering analysts.
Frequently asked questions
UTRS forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month UTRS price target is $100.00, with a high forecast of $100.00 and a low of $100.00. The median price target is shown in the chart above when available. This implies +99999903.0% potential upside from the current price of $0.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.